NovaBridge Biosciences
NBP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $1 | $6 | $4 |
| G&A Expenses | $4 | $4 | $7 | $8 |
| SG&A Expenses | $4 | $4 | $7 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $5 | $13 | $12 |
| Operating Income | -$7 | -$5 | -$13 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $3 | -$8 |
| Pre-Tax Income | -$6 | -$3 | -$11 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$3 | -$9 | -$20 |
| % Margin | – | – | – | – |
| EPS | -0.069 | -0.28 | -0.11 | -0.25 |
| % Growth | 75.4% | -154.5% | 56% | – |
| EPS Diluted | -0.069 | -0.28 | -0.11 | -0.25 |
| Weighted Avg Shares Out | 82 | 82 | 81 | 81 |
| Weighted Avg Shares Out Dil | 82 | 82 | 81 | 81 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $6 |
| EBITDA | -$7 | -$5 | -$12 | -$6 |
| % Margin | – | – | – | – |